Does Rallies show 13F holders for AVBP?

Yes. Rallies tracks hedge fund and 13F ownership data for AVBP, including fund names, share counts, latest tracked quarter, and position changes when available.

Is AVBP research on Rallies investment advice?

No. Rallies provides research, data, and educational context for AVBP. It does not provide personalized investment advice.

AVBP (ArriVent BioPharma, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

ArriVent BioPharma, Inc. Common Stock (AVBP) is a publicly traded Healthcare sector company. As of May 20, 2026, AVBP trades at $27.24 with a market cap of $1.26B and a P/E ratio of -6.20. AVBP moved +4.09% today. Year to date, AVBP is +39.38%; over the trailing twelve months it is +30.49%. Its 52-week range spans $15.47 to $36.37. Analyst consensus is strong buy with an average price target of $44.33. Rallies surfaces AVBP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns AVBP stock?

Hedge funds tracked by Rallies that own AVBP include Orbimed Advisors and Cooperman Leon. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for ArriVent BioPharma, Inc. Common Stock.

AVBP Key Metrics

Key financial metrics for AVBP
Metric	Value
Price	$27.24
Market Cap	$1.26B
P/E Ratio	-6.20
EPS	$-4.32
Dividend Yield	0.00%
52-Week High	$36.37
52-Week Low	$15.47
Volume	400.19K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-166.31M
Gross Margin	0.00%

Top Hedge Funds Holding AVBP

Orbimed Advisors holds 3.03M shares of AVBP, changed +0.00% as of Mar 31, 2026.
Cooperman Leon holds 421.28K shares of AVBP, changed +0.00% as of Sep 30, 2025.

Latest AVBP News

ArriVent Banks $326.4M Cash, ARR-002 IND Cleared, Firmonertinib Data Due Mid-2026 — May 11, 2026
ArriVent Secures FDA Clearance for ARR-002 IND, Phase 1 Trial Slated H2 2026 — May 7, 2026
ArriVent to Present Firmonertinib Phase 3 Supporting Data and ARR-002 ADC Efficacy — Mar 17, 2026
ArriVent Secures $312.8M Cash Runway Through 3Q 2027, Phase 3 Data Due Mid-2026 — Mar 5, 2026

Recent AVBP Insider Trades

HILLHOUSE INVESTMENT MANAGEMENT, LTD. sold 555.55K (~$12.98M) on Dec 10, 2025.
HILLHOUSE INVESTMENT MANAGEMENT, LTD. bought 555.55K (~$10.00M) on Jan 30, 2024.
ORBIMED ADVISORS LLC bought 222.22K (~$4.00M) on Jan 30, 2024.

AVBP Analyst Consensus

9 analysts cover AVBP: 0 strong buy, 9 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $44.33.

Common questions about AVBP

Who owns AVBP stock?: Hedge funds tracked by Rallies that own AVBP include Orbimed Advisors and Cooperman Leon. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for ArriVent BioPharma, Inc. Common Stock.
Does Rallies show 13F holders for AVBP?: Yes. Rallies tracks hedge fund and 13F ownership data for AVBP, including fund names, share counts, latest tracked quarter, and position changes when available.
Is AVBP research on Rallies investment advice?: No. Rallies provides research, data, and educational context for AVBP. It does not provide personalized investment advice.